Literature DB >> 10395109

Biotinylation of class I MHC molecules abrogates recognition by W6/32 antibody.

P Malik1, E Baba, J L Strominger.   

Abstract

W6/32 is one of the most common monoclonal antibodies (mAb) used to characterize human class I major histocompatibility complex (MHC) molecules. It recognizes a conformational epitope on the intact MHC molecule containing both beta2-microglobulin (beta2-m) and the heavy chain. Labelling proteins by biotinylation is a very useful technique of for their detection, purification and analysis. A common method for biotinylating proteins is through the use of N-hydroxysuccinimide (NHS) biotin or Sulfo-NHS-biotin where the free amino groups on the protein are used for coupling the biotin moiety. However, W6/32 was unable to effectively immunoprecipitate biotinylated human class I MHC molecules including the human non-classical HLA-G molecule. FACScan analysis confirmed that biotinylating human class I MHC and HLA-G molecules prevents the recognition of these molecule by W6/32. In contrast, the recognition by another conformation-dependent monoclonal antibody, ME1, specific to HLA-B27 molecules, remained totally unaffected.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395109     DOI: 10.1034/j.1399-0039.1999.530609.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  3 in total

1.  MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A.

Authors:  S B Deitz; D A Dodd; S Cooper; P Parham; K Kirkegaard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment.

Authors:  Navreet K Nanda; Lynn Birch; Norman M Greenberg; Gail S Prins
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

Review 3.  Homotypic and heterotypic in cis associations of MHC class I molecules at the cell surface.

Authors:  Fernando M Ruggiero; Sebastian Springer
Journal:  Curr Res Immunol       Date:  2022-05-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.